Trends in frequency of HIV viral load and CD4 cell count monitoring among Asian cohort of adults with HIV: an analysis of the TREAT Asia HIV Observational Database, 2003-2018

This study analyzing the TREAT Asia HIV Observational Database from 2003 to 2018 reveals that while viral load testing rates remained stable, CD4 testing frequency declined over time, with both monitoring patterns significantly influenced by demographic, clinical, and socio-economic factors, though neither was strongly associated with AIDS diagnosis and frequent CD4 testing was paradoxically linked to higher mortality risk.

The Gist

Imagine the human body as a bustling city under siege by an invisible enemy: HIV. To keep the city safe, doctors use two main tools to check on the health of the defenses:

1. The Viral Load (VL) Test: This is like a smoke detector. It measures how much "fire" (the virus) is currently burning in the city. If the smoke detector is silent (low viral load), the fire is out, and the treatment is working.
2. The CD4 Count Test: This is like a headcount of the police force. It counts how many immune cells (the police) are left to defend the city. If the police force is small, the city is vulnerable.

For a long time, doctors checked both the smoke detector and the police headcount at every single visit. But as medicine advanced, experts realized that if the smoke detector is silent, you don't need to count the police every day. You just need to make sure the fire stays out.

The Story of the Study

This paper is a report card from a massive group of doctors across 12 Asian countries (from Japan to India, Thailand to Vietnam) who watched over 8,446 people living with HIV between 2003 and 2018. They wanted to see how the "checking habits" changed over time and if those habits helped people stay alive.

Here is what they found, translated into everyday terms:

1. The Shift in Checking Habits

• The Smoke Detector (Viral Load): The frequency of checking the smoke detector stayed steady at about once a year. It didn't go up or down much. It was like a reliable clock that kept ticking.
• The Police Headcount (CD4): This changed a lot. In 2003, doctors were counting the police twice a year. By 2018, they were only doing it once a year.
  • Why? Because the world's health guidelines changed. They realized that once the fire is out (viral load is low), constantly counting the police isn't necessary. It saves money and time, allowing doctors to focus on the most important thing: keeping the fire out.

2. Who Got Checked More Often?

Not everyone got the same amount of attention. The study found that checking happened more often for certain groups, almost like a "VIP treatment" based on specific factors:

• Richer Countries: People in wealthier nations (like Singapore or South Korea) got tested much more often than those in poorer nations. It's like having a city with a bigger budget for security checks.
• Older Adults: Older patients were checked more frequently than younger ones. Younger people were more likely to "drift away" from the clinic (like a commuter missing the bus), so their checks were less frequent.
• The "Troubled" Cases: If a patient had a high viral load (the fire was still smoldering) or was on a more complex medication, they got checked more often. It's like a mechanic checking a car with a sputtering engine more often than one that runs smoothly.
• The "Hidden" Groups: Sadly, people who inject drugs, men who have sex with men (MSM), or those with Hepatitis C got checked less often. This suggests these groups might be falling through the cracks of the healthcare system, perhaps due to stigma or difficulty accessing care.

3. Did the Checks Save Lives?

This is the most interesting part.

• The Smoke Detector: How often they checked the smoke detector didn't directly predict who would get sick with AIDS.
• The Police Headcount: Here's a twist. People who got their "police headcount" (CD4 test) done very frequently (more than twice a year) actually had a higher risk of dying.
  • Wait, why? It sounds backwards! But think of it this way: You don't call the police to a party because you're having fun; you call them because there's a riot. Doctors ordered these extra tests because the patients were already very sick or had low immune counts. The frequent testing was a symptom of being in trouble, not the cause of the trouble.

The Big Takeaway

This study tells us that the healthcare system in Asia is evolving. It is moving away from "checking everything, everywhere, all the time" toward a smarter, more targeted approach.

• The Good News: We are getting better at using the "smoke detector" (Viral Load) to keep the fire out, which is the gold standard for treatment.
• The Challenge: We need to make sure that the "VIP treatment" (frequent testing) isn't just for the rich or the older, and that we aren't ignoring the "hidden" groups (like drug users or MSM) who might need the most help.
• The Future: The goal is Differentiated Care. This means treating every patient like a unique individual. If your fire is out and you're stable, we check less often to save resources. If you are struggling, we check more often to keep you safe.

In short, the doctors are learning to be smarter detectives, using the right tools at the right time to keep the city of the body safe, while trying to ensure no one gets left behind in the shadows.

Technical Summary

1. Problem Statement

Despite World Health Organization (WHO) guidelines recommending routine Viral Load (VL) testing as the primary method for monitoring Antiretroviral Therapy (ART) effectiveness and targeted CD4 testing for patients on stable ART, the global scale-up of VL monitoring has been slow, particularly in low- and middle-income countries (LMICs). Barriers include cost, limited laboratory infrastructure, and staff training gaps. Furthermore, there is uncertainty regarding the optimal role of CD4 monitoring in the era of "Treat-All" policies. This study addresses the gap in understanding how these global recommendations have translated into actual clinical practice within the Asia-Pacific region over a 15-year period.

2. Methodology

• Study Design & Population: A retrospective analysis of data from the TREAT Asia HIV Observational Database (TAHOD), a multicenter cohort study involving 21 sites across 12 Asia-Pacific countries (Cambodia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam).
• Inclusion Criteria: Adults enrolled between 2003 and 2018 who had been on ART for at least one year and remained in the cohort for at least one year.
• Exclusion Criteria: Patients transferred out, lost to follow-up (LTFU), or died within the first year of cohort enrollment.
• Statistical Analysis:
  • Trend Analysis: VL and CD4 testing rates (per person-years, PYS) were plotted across calendar years.
  • Association Analysis: Poisson regression models with random effects were used to identify factors associated with testing frequencies (Incidence Rate Ratios - IRR).
  • Outcome Analysis: Fine and Gray competing risk regression models were employed to evaluate the association between testing frequencies and two primary outcomes: new AIDS diagnosis and mortality, with LTFU treated as a competing risk.
  • Covariates: Demographics (age, sex, exposure mode), clinical factors (current VL, CD4 count, ART regimen, coinfections), and socio-economic factors (country income level).

3. Key Contributions

• Longitudinal Regional Data: Provides the first comprehensive, long-term (2003–2018) analysis of monitoring trends specifically within the diverse Asia-Pacific region, covering both high-income and resource-limited settings.
• Disentangling VL and CD4 Trends: Quantifies the inverse relationship between the adoption of VL testing and the decline in CD4 testing, highlighting how guideline shifts have impacted clinical behavior.
• Risk Stratification Insights: Identifies specific demographic and clinical subgroups (e.g., MSM, people who inject drugs, younger patients) that are systematically under-monitored, suggesting disparities in care retention.
• Outcome Correlation: Investigates the counter-intuitive finding that higher CD4 testing frequency correlates with higher mortality, interpreting this as a marker for clinical vigilance in high-risk patients rather than a causal factor.

4. Key Results

Study Population:

• N = 8,446 patients.
• Median age at ART initiation: 34 years; 69.6% male.
• Primary exposure mode: Heterosexual contact (64.1%).
• Median follow-up: 8.2 years.

Monitoring Trends:

• Viral Load (VL): Testing rates remained relatively stable at ~1.0 test/PYS throughout the study period.
• CD4 Cell Count: Testing rates declined significantly from 2.04 tests/PYS (2003) to 1.06 tests/PYS (2018).

Factors Associated with Testing Frequency:

• Higher VL Testing: Associated with later calendar years (2008–2015), older age (>30), higher current VL (>400 copies/mL), non-NRTI+NNRTI regimens, and residence in upper-middle or high-income countries (IRR 2.17 and 3.14, respectively).
• Lower VL Testing: Observed in Men who have Sex with Men (MSM), people who inject drugs (IDU), those with unknown exposure modes, and Hepatitis C co-infected patients.
• Higher CD4 Testing: Associated with older age, female sex, higher VL, and residence in higher-income countries.
• Lower CD4 Testing: Associated with MSM/IDU exposure, higher current CD4 counts (>200 cells/µL), and NRTI+PI regimens.

Clinical Outcomes:

• AIDS Diagnosis: Neither VL nor CD4 testing frequency was significantly associated with the risk of new AIDS diagnoses. However, risk decreased in later calendar years and with higher CD4 counts.
• Mortality:
  • VL testing frequency was not associated with mortality.
  • Crucial Finding: Having >2 CD4 tests in the previous year was associated with a higher risk of mortality (SHR = 1.43). The authors attribute this to "confounding by indication," where sicker patients (low CD4) receive more frequent monitoring.
  • Other mortality risk factors included older age, switching ART regimens, high VL, and prior AIDS diagnosis.

5. Significance and Conclusion

• Implementation Gap: The study confirms that while VL monitoring is the gold standard, its implementation in Asia-Pacific remains uneven, heavily dependent on country income levels. Low- and middle-income countries lag behind in routine VL testing adoption.
• Differentiated Care: The data supports the need for differentiated service delivery. Specific populations (MSM, IDU, younger adults) face barriers to retention and consistent monitoring, requiring targeted interventions.
• Role of CD4 Testing: While CD4 testing frequency is declining as guidelines shift toward VL, the study reinforces that CD4 remains critical for risk stratification. The association between frequent CD4 testing and higher mortality underscores the need to continue monitoring patients with advanced disease or immunologic failure.
• Policy Implication: To improve outcomes, the region must invest in laboratory capacity to scale up VL testing while maintaining strategic CD4 testing for identifying advanced HIV disease. Recognizing the socio-economic and demographic drivers of monitoring gaps is essential for optimizing HIV care in the Asia-Pacific region.